Barry Flannelly: Sure, Navin. This is Barry. So as far as patient retention, I guess what you mean is that how many patients. So obviously, the vitiligo patients stay on for a much longer period of time. Of course, atopic dermatitis patients, patients with eczema, they have flares, they use Opzelura it goes away, and it’s very effective. So, some patients get immediate relief. Obviously, we talk about the itch relief all the time to get good itch relief and then the skin begins to clear over time. So these patients will come back, we think, year after year as long as they have their eczema and use the drug when they see the flares until it goes away and then start using it again. Vitiligo patients, we’ve seen from our long-term data, patients can use the drug for twp years and continue to get benefit.
So that’s what we keep on reinforcing around education so that patients understand how to use the drug, what they’re going to see at three months, six months, nine months, 12 months and beyond, and that’s how we’ll continue to retain them. Yes, it’s very important, the strategies around patients’ adherence, particularly for vitiligo, and particularly, we know we can make improvements around what healthcare professionals, dermatologists and their offices are telling the patient how to use the drug and then the patients themselves understanding how to use the trend. As far as competitors in the MF space, I mean, there are three other JAK inhibitors approved for myelofibrosis, where we continue to be the market leader in myelofibrosis, we’ll continue to be.
As far as the combinations that have been studied recently, we’ll see. But it certainly does expand the market because you have the opportunity of going early, earlier patients starting. We know if they start early with Jakafi, their survival advantages could be better. And then, in fact, they’ll go to second-line drugs and third-line drugs. So yes, we created the market, and it could expand if there are good drugs approved after Jakafi.
Operator: Thank you. Our final question today is coming from Matt Phipps from William Blair. Your line is now live.
Matt Phipps: Thanks for squeezing me in. I’ll just ask one on the CDK2 inhibitor. Curious if you can comment on the safety profile you’ve seen so far if you’re seeing any ocular tox or cytopenia? Thank you.
Pablo Cagnoni: Yes, thank you for the question. We have not. We are happy with the safety profile so far, which is consistent with the mechanism of CDK2 inhibition. And we have not seen ocular toxicity, which, as you know, led to a clinical hold in one of our competitors. So, we’re very excited about the early data of our CDK2 inhibitor, as we mentioned. And we look forward to sharing data over the course of the year as well as our future development plans for the CDK2 inhibitor program.
Operator: Thank you. We reached the end of our question-and-answer session. I’d like to turn the floor back over for any further or closing comments.
Ben Strain: Thank you for participating in today’s call and for your questions. The IR team will be available for the rest of the day. Thank you.
Operator: Thank you. That does conclude today’s teleconference webcast. You may disconnect your line at this time, and have a wonderful day. We thank you for your participation today.
